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Abstract
Background: While the association of human papillomavirus (HPV) with cervical cancer is well established, the
influence of HIV on the risk of this disease in sub-Saharan Africa remains unclear. To assess the risk of invasive
cervical carcinoma (ICC) associated with HIV and HPV types, a hospital-based case-control study was performed
between September 2004 and December 2006 in Kampala, Uganda. Incident cases of histologically-confirmed ICC
(N=316) and control women (N=314), who were visitors or care-takers of ICC cases in the hospital, were recruited.
Blood samples were obtained for HIV serology and CD4 count, as well as cervical samples for HPV testing. HPV
DNA detection and genotyping was performed using the SPF10/DEIA/LiPA25 technique which detects all mucosal
HPV types by DEIA and identifies 25 HPV genotypes by LiPA version 1. Samples that tested positive but could not
be genotyped were designated HPVX. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by
logistic regression, adjusting for possible confounding factors.
Results: For both squamous cell carcinoma (SCC) and adenocarcinoma of the cervix, statistically significantly
increased ORs were found among women infected with HPV, in particular single HPV infections, infections with
HPV16-related types and high-risk HPV types, in particular HPV16, 18 and 45. For other HPV types the ORs for both
SCC and adenocarcinoma were not statistically significantly elevated. HIV infection and CD4 count were not
associated with SCC or adenocarcinoma risk in our study population. Among women infected with high-risk HPV
types, no association between HIV and SCC emerged. However, an inverse association with adenocarcinoma was
observed, while decrease in CD4 count was not associated with ICC risk.
Conclusions: The ORs for SCC and adenocarcinoma were increased in women infected with HPV, in particular
single HPV infections, infections with HPV16- and 18-related types, and high-risk HPV types, specifically HPV16, 18
and 45. HIV infection and CD4 count were not associated with SCC or adenocarcinoma risk, but among women
infected with high-risk HPV types there was an inverse association between HIV infection and adenocarcinoma risk.
These results suggest that HIV and CD4 count may have no role in the progression of cervical cancer.
Background
Human papillomavirus (HPV) infection is a necessary
cause for the development of cervical cancer, and the
risk of cervical cancer differs [1] according to HPV type.
HIV infection has also been associated with cervical
cancer risk [2], which seems to vary according to co-
infection with different HPV types [3,4]. The association
between HIV and cervical cancer appears to be less evi-
dent in low-income countries, notably sub-Saharan
Africa, than in high-income countries [5,6]. Two studies
conducted at the beginning of the AIDS epidemic in
Uganda [7] and Tanzania [8], which assessed HIV infec-
tion and cervical cancer, showed no association. How-
ever, a positive association has been observed in
Western countries such as Italy, France and Spain
[5,9,10], as well as in some recent studies from Uganda
[11] and Tanzania [12]. Whether these differences in
cervical cancer risk between studies can be explained by
differences in co-infection with specific HPV types
remains unclear.
We present here results from a study of invasive cervi-
cal carcinoma (ICC) in relation to HPV status, HIV sta-
tus and CD4 count in Uganda, where the estimated
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rising and is now 52.4 per 100 000 women [13].
Methods
We conducted a hospital-based case-control study in
Mulago Hospital in Kampala, Uganda, which is the
national referral and teaching hospital for Makerere
University. The hospital admits about 30 ICC cases each
month.
Patients attending the gynaecological clinics or emer-
gency section are mostly residents of Kampala City and
the surrounding areas, with a population of about 1 000
000, although some come directly from areas outside
Kampala. Like most urban areas of Uganda, HIV preva-
lence is relatively high in Kampala [14]. Recruitment of
ICC cases and control women was done by selected
nurses and midwives working in the gynaecological
wards or clinics, using the inclusion and exclusion cri-
teria described below.
Recruitment of ICC cases
Patients eligible for the study were women aged 18 to
74 years, residents of Uganda for at least 2 years and
consecutively diagnosed with incident ICC during the
period September 2004 to September 2006. ICC cases
recruited had not yet undergone primary treatment,
signed a written informed consent form to participate in
the study, and were able to provide biological samples.
ICC cases were excluded if tissue and blood samples
could not be collected because they were in a terminal
stage, or for any other reason that might interfere with
established patterns of patient care.
Recruitment of control women
At the Mulago Hospital, all hospitalised patients have
one or more accompanying persons, who are responsi-
ble for preparing food and taking care of basic hygiene
needs and other patient requirements. These accompa-
nying persons are in general female members of the
same family or clan. Control women were recruited
among those accompanying or visiting ICC cases. The
motivation to enrol relatives of the cancer patients as
controls was to avoid bias by including control women
who would most likely live in the same areas of the
country as the ICC cases and would have a similar
social background. In addition, control women would
probably have used the same hospital as the ICC cases
if they had had a cervical cancer diagnosis. Since the
evaluation of family history of cervical cancer was not
part of our study hypothesis, the inclusion of blood rela-
tives of ICC cases did not constitute a problem.
Control women were frequency matched to ICC cases
by 5-year age groups. Inclusion criteria for control
women were the same as for ICC cases (i.e. resident of
Uganda for at least 2 years, aged 18 to 74 years between
September 2004 and December 2006, able to give
informed consent and willing to provide biological sam-
ples), save the cervical cancer diagnosis.
Control women were offered a pelvic examination
with visual inspection of the cervix uteri and Pap smear
screening test. Test results were made available to con-
trol women before they left the hospital (i.e. during the
period of hospitalisation of the ICC cases they accompa-
nied). Women in whom pre-malignant and malignant
cervical abnormalities were suspected or detected were
referred for standard follow-up diagnosis and treatment
at Mulago Hospital. A symptomatic diagnosis of cervical
and vaginal infections was done by the gynaecologists
examining control women, and appropriate antibiotic
treatment was offered free of charge whenever indicated.
Collection of biological samples and study procedures
Information about reproductive history, lifestyle prac-
tices and sexual behaviour was assessed using a standar-
dised questionnaire administered by the nurses or
midwives recruiting ICC cases and control women.
Blood was obtained for a full blood count, HIV serologi-
cal testing, and CD4 count. All subjects underwent pel-
vic and abdominal examinations, and cervical samples
were obtained for diagnosis and HPV detection.
For ICC cases, biopsies of the cervical lesions were
collected under general anaesthesia. Samples were
immediately stored in sterile specimen tubes and trans-
ported in a flask containing ice to the pathology labora-
tory. There the specimen was divided into two parts:
one part was fixed in 10% buffered formalin (for 12 to
24 hours) for histological processing and diagnosis, and
the other half was kept in a Nunc tube, labelled and
stored at -70°C until shipped for HPV testing. Biopsy
samples were processed using the automatic tissue pro-
cessor; they were paraffin embedded, sectioned at 4 μm
thickness and stained with Haematoxylin and Eosin.
For control women, exfoliated cervical cells were col-
lected with two Cervex brushes before any treatment for
cervical or vaginal infection was administered. The first
brush was rinsed in PreservCyt solution (ThinPrep,
Hologic, Marlborough, MA, USA) according to the
manufacturer’s instructions and kept at room tempera-
ture until shipped to the laboratory for HPV testing.
The second brush was used to make a smear and
stained with Pap stain; smears were classified as normal
or abnormal. All histological and cytological diagnoses
were done by a pathologist at the Department of Pathol-
ogy, Makerere University.
HIV testing and CD4 count
HIV was measured using a rapid test [15], which was
the recommended test in Uganda during the study
Odida et al. Infectious Agents and Cancer 2011, 6:8
http://www.infectagentscancer.com/content/6/1/8
Page 2 of 13period (Ministry of Health of Uganda). Briefly, blood
was initially tested by the Capillus method (Capillus
HIV-1/HIV-2 (CP) (Trinity Biotech, Galway, Ireland).
Negative results were reported as negative, and no other
confirmatory test was done. For positive results a confir-
matory test using Serocard (Trinity Biotech, Galway, Ire-
land) was performed. When results from Serocard were
positive, they were reported as positive. However, if the
results from Serocard were negative, a tiebreaker test
using the Multispot test (Bio-Rad Laboratories, Her-
cules, CA, USA) was applied, and the results reported as
negative or positive depending on the results of this
test. All tests were done according to the manufacturer’s
instructions. HIV was assessed as positive (exposed) or
negative (not exposed). These test algorithms have 100%
sensitivity and specificity [15]. CD4 count was done
using flow cytometry with the Becton Dickinson FACS-
Count automated instrument (BD FACSCount™,B D
Biosciences, Franklin Lakes, NJ, USA).
HPV testing
The frozen ICC samples and the exfoliated cervical cell
samples (in ThinPrep) from control women were
shipped to DDL Diagnostic Laboratory (DDL), Voor-
burg, the Netherlands, for HPV analysis. Frozen samples
were shipped in dry ice, while ThinPrep samples were
shipped at room temperature. DNA was extracted from
the frozen biopsy sections using proteinase K. From the
suspension of cervical cells, DNA was isolated by use of
a MagNA Pure LC instrument (Roche Diagnostics,
Indianapolis, IN, USA) using the total nucleic acid isola-
tion kit (Roche Diagnostics).
SPF10 PCR was performed using 10 μli s o l a t e dD N A
in a final reaction volume of 50 μl. Ten μlo ft h e
amplified PCR product was tested with a cocktail of
general probes recognising at least 54 mucosal HPV
types in a microtitre plate format for the detection of
HPV DNA by use of DNA enzyme immunoassay
(DEIA). Optical densities (OD450)w e r er e a do na
microtitre plate reader. Subsequently, for HPV DNA-
positive samples, 10 μlo ft h es a m eS P F 10 amplimer
was genotyped by the SPF10-LiPA25 test (version 1,
produced at Labo Biomedical Products, Rijswijk, the
Netherlands). By reverse hybridisation of the SPF10
amplimer with 28 different probes on the LiPA strip,
25 HPV genotypes can be identified: HPV6, 11, 16, 18,
31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56,
58, 59, 66, 68/73, 70, 74. The sequence variation within
the SPF10 primers allows the recognition of these dif-
ferent HPV genotypes, except for HPV68 and 73, as
their innerprimer regions are identical and cannot be
distinguished in this test. The positive hybridisation on
t h es t r i p si sv i s u a l i s e da sap u r p l eb a n db ym e a n so fa
precipitating colour substrate on the probe site.
Samples that were HPV DNA-positive by SPF10 PCR-
DEIA, but for which no type was identified by the
LiPA25 strip, were designated as HPVX.
For HPV-negative ICC cases, a beta-globin PCR was
performed to assess the quality of DNA isolated from
the biopsy.
Ethical consideration
The study protocol was approved by the Higher
Degree’s Research Committee of the Faculty of Medi-
cine, Makerere University, and the Uganda National
Council of Science and Technology. The study also
complied with the ethical norms of Mulago Hospital
and those of the Ministry of Health of Uganda. All the
study participants signed a written informed consent
form before inclusion in the study.
Data analysis
Our analytical strategy was based on the assumption
that normal cervical cells persistently infected with
high-risk HPV types may undergo several mutations,
which can eventually lead to the development of ICC. In
our study cervical samples for HPV testing were col-
lected at the time of cancer diagnosis (and correspond-
ing calendar time among control women). Therefore
HPV infections are only to be considered as indicators
of persistent HPV infection(s).
We also wanted to test the hypothesis that HIV infec-
tion per se is associated with cervical cancer risk (as this
is a question mark in the literature), and moreover
whether the lowered immunity caused by HIV infection
or by other causes (as reflected by decreased CD4
count) is associated with this risk. HIV infection and
decline in CD4 count may increase the probability of
acquiring an HPV infection, or decrease the probability
of clearing an HPV infection.
To evaluate the risk of ICC, SCC and adenocarcinoma
were analysed separately, and odds ratios (OR) and cor-
responding two-sided 95% confidence intervals (CI)
were calculated using logistic regression models. To
address the problem of small sample sizes, we calculated
the logistic regression using Firth’s penalised likelihood
approach [16]. As a consequence of the small sample
size it was only possible to estimate the lower or upper
limit of the CI for some ORs. We fitted age-adjusted
models for SCC and adenocarcinoma of the cervix for
women classified according to:
a) Each HPV type or group of HPV types,
b) HIV status (positive or negative),
c) CD4 count per 100 cell decrease, as a linear con-
tinuous variable(s),
d) Each HPV type and group of HPV types in sub-
groups of women classified according to HIV status,
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or ≤300 and >500 or ≤500 cells) among women who
were infected with high-risk HPV types only.
T h eg r o u p so fH P Vt y p e sa n a l y s e dw e r e“any HPV
infection"; “single HPV infections” for any HPV infection
except HPVX; “multiple HPV infections”,i . e .c o n c o m i -
tant infection with more than one HPV type, except for
HPVX; “high-risk HPV types” for infections with any of
the HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68 or 73; “low-risk HPV types” for infections with
any of the HPV types 6, 11, 34, 40, 42, 43, 44, 53, 54,
66, 70 or 74; “HPV16-related types” for any of the HPV
types 16, 31, 33, 35, 52 or 58; “HPV18-related types” for
any of the types 18, 39, 45, 59 or 68; and HPVX.
In the analysis of ICC risk according to HIV status,
adjustment for CD4 count was done to rule out the pos-
sibility that HIV had an influence on risk before affect-
ing immune status (reflected by a decrease in CD4
count).
The statistical software SAS version 9.2 procedure
logistic was used for all analyses. All tests of statistical
hypotheses were made on the two-sided 5% level of
significance.
Results
During the study period, 484 women with a diagnosis
of preliminary incident ICC and 385 control women
were approached and invited to participate in the
study. Sixty-six (66) potential ICC cases and 22 control
women declined to participate, and 41 ICC cases and
44 control women were excluded due to incomplete
questionnaires or inability to provide biological sam-
ples. Further, 61 potential ICC cases were excluded
because ICC diagnosis was not confirmed by histology,
as well as five control women who had cervical lesions
compatible with cervical intraepithelial neoplasia
(CIN). Thus, a total of 316 ICC cases (265 SCC, 42
adenocarcinomas, 5 mixed histology and 4 other his-
tology) and 314 control women were recruited into the
study. Of these, cervical samples for HPV testing were
obtained from 255 ICC cases (215 SCC, 32 adenocarci-
nomas and 8 other histological types) and 309 con-
trols. Following HPV testing, 16 of the 255 ICC cases
had to be excluded as their samples were beta-globin-
negative, leaving 239 ICC cases in the final analysis
(Table 1).
The clinical and demographic characteristics of study
participants are shown in Table 2. A smaller proportion
of ICC cases than control women had ever had a Pap
smear, and ICC cases had proportionally more HPV
infections than control women.
A m o n gt h e2 3 9I C Cc a s e sa n d3 0 9c o n t r o lw o m e n ,
HPV DNA was detected in 222 (92.9% of 239) and 95
(30.7% of 309) women, respectively. Seventeen ICC
cases (7.1%) were HPV-negative.
There were no other statistically significant differences
between ICC cases and control women regarding char-
acteristics, including HIV positivity. The HIV test was
Table 1 Subject enrolment and measurements
Cases % Controls %
Women invited to participate 484 100.0 385 100.0
Declined to participate 66 13.6 22 5.7
Incomplete questionnaires 41 8.5 44 11.4
Diagnosis not confirmed
a 61 12.6 5 1.3
Total preliminarily recruited
b 316 100.0 314 100.0
Samples for HPV testing
b 239
c 75.6 309 98.4
Samples for HIV testing
b 281 88.9 308 98.1
Combined HIV and HPV samples
b 222 70.3 303 96.5
Invasive cervical carcinoma study in Kampala, Uganda
a Diagnosis of invasive cervical carcinoma not confirmed by histology for
cases; control women found with abnormal cervical smears (cervical
intraepithelial neoplasia, not invasive cervical carcinoma).
b Percent based on total recruited.
c In addition to these 239, 16 cases were beta-globin-negative and therefore
excluded from all analyses.
Abbreviations: HPV: human papillomavirus.
Table 2 Clinical and demographic characteristics of
invasive cervical carcinoma cases and control women
Cases
a Controls
N%
b N%
b
Number of women 316 314
Mean age, years (SD) 47 11.5 41 12.5
Mean age at first intercourse, years (SD) 16 3.0 16 3.0
Mean parity (SD) 6.9 5.8 4.8 4.0
Mean CD4 count (SD) 722 375 843 389
Ever used contraceptives 103 32.6 111 35.4
HIV status (+)
c 55 18.8 54 17.5
Had attended school 207 65.5 271 86.3
Ever smoked 26 8.2 26 8.3
Partner is a current smoker 76 24.1 67 21.3
Alcohol consumption 131 41.5 133 42.4
History of sexually transmitted diseases 148 46.8 137 43.6
Ever had Pap smear 6 1.9 13 4.1
HPV tested 239 75.6 309 98.4
HPV detected 222 92.9
d 95 30.7
d
HPV not detected 17
e 7.1
d 214 69.3
d
Invasive cervical carcinoma study in Kampala, Uganda
a Number of women with: squamous cell carcinoma: 265, adenocarcinoma: 42,
mixed histology: 5, other: 4.
b Percent where applicable.
c HIV positivity based on available data for 293 cases and 308 controls.
d Percentage (%) of tested.
e Additional 16 invasive cervical carcinoma patients had available samples, but
these were beta-globin-negative, indicating poor sample quality, and
therefore were excluded from all analyses.
Abbreviations: SD: standard deviation, HPV: human papillomavirus.
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women (Table 2).
SCC and HPV infection
For SCC, the age-adjusted ORs were statistically signifi-
cantly increased for any HPV infection (OR 50.8, 95%
CI: 25.8-113.9), single HPV infections (OR 33.3, 95% CI:
20.2-56.7), HPV16-related types (OR 11.6, 95% CI: 7.5-
18.5), HPV18-related types (OR 9.4, 95% CI: 5.3-17.4),
and high-risk HPV types (OR 64.5, 95% CI: 35.4-126.6),
in particular HPV16 (OR 29.1, 95% CI: 15.4-60.7),
HPV18 (OR 9.6, 95% CI: 4.6-22.3), and HPV45 (OR
58.7, 95% CI: lower limit >7.9).
Multiple HPV infections and infections with low-risk
HPV types were not associated with an increased OR
for SCC. Adjustment for HIV as well as decline in CD4
c o u n t( - 1 0 0c e l l s )d i dn o ts u b s t a n t i a l l yc h a n g et h eO R
estimates among the different groups of HPV types
(Table 3).
SCC according to HPV type in HIV-negative and -positive
women
The association between infection with different HPV
types and SCC was rather similar in HIV-negative and
-positive women. However, the number of HIV-posi-
tive SCC in our study (N = 42) was limited, and there-
fore the CIs of our OR estimates were rather broad
(Table 4).
Adenocarcinoma and HPV infection
The ORs for adenocarcinoma were statistically signifi-
cantly increased for any HPV infection (OR 12.9, 95%
CI: 5.0-41.8), single HPV infections (OR 13.7, 95% CI:
6.0-34.0), infection with HPV16-related types (OR 3.6,
95% CI: 1.5-8.2), HPV18-related types (OR 22.8, 95% CI:
9.3-58.9), and high-risk HPV types, in particular HPV
16 (OR 11.6, 95% CI: 4.3-31.8), 18 (OR 18.5, 95% CI:
6.6-54.4) and 45 (OR 297.4, 95% CI: lower limit >26.4).
Adjustment for HIV status as well as decline in CD4
c o u n t( - 1 0 0c e l l s )d i dn o ts u b s t a n t i a l l yc h a n g et h eO R
for the different groups of HPV types (Table 5).
Adenocarcinoma according to HPV type in HIV-negative
and -positive women
Given the very low number of HIV-positive adenocar-
cinomas (N = 4) in our study, our risk estimates are
not sufficiently precise to reach any conclusions about
differences between HIV-negative and -positive
women, but there was no evidence of a difference in
risk (Table 6).
SCC and adenocarcinoma according to HIV status
Table 7 shows the overall OR for SCC and adenocarci-
noma in relation to HIV infection. There was no
association between HIV positivity and SCC (OR 1.5,
95% CI: 0.9-2.3) or adenocarcinoma (OR 1.1, 95% CI:
0.4-2.7) in age-adjusted models.
In statistical models adjusting for age and decline in
CD4 count (-100 cells), HIV-positive women had an
increased OR for SCC (OR 1.6, 95% CI: 1.0-2.6) of bor-
derline significance. However, the OR for SCC among
HIV-positive women was no longer statistically signifi-
cant after further adjustment for different groups of
HPV infections (adjustment for age, CD4 count and any
H P Vi n f e c t i o n :O R0 . 8 ,9 5 %C I :0 . 4 - 1 . 4 ) ,e x c e p tw h e n
we adjusted for infection with low-risk HPV types alone
(OR 1.9, 95% CI: 1.1-3.2) and multiple HPV infections
(OR 1.8, 95% CI: 1.1-3.0), when the lower CIs were of
borderline statistical significance (Table 7). There was
no evidence of association between HIV infection and
adenocarcinoma in any of the statistical models tested
in Table 7.
SCC and adenocarcinomas according to CD4 count
Decline in CD4 count (-100 cells) was not statistically
significantly associated with SCC (OR 1.2, 95% CI: 1.0-
1.4) or adenocarcinoma (OR 0.8, 95% CI: 0.1-2.6) in
age-adjusted models including all women with available
i n f o r m a t i o ni nt h es t u d y ,n o ri na n a l y s e sa d j u s t i n gf o r
HIV and individual HPV types, or groups of HPV types
(data not shown).
HIV infection, CD4 count and SCC and adenocarcinoma
risk among women infected with high-risk HPV types
Table 8 shows the overall age-adjusted OR for SCC and
adenocarcinoma according to HIV infection and decline
in CD4 count (-100 cells) among women who were
infected with high-risk HPV types (i.e. ICC cases and
control women who were not infected with a high-risk
HPV type were excluded from this analysis). HIV posi-
tivity was not associated with SCC risk (OR 0.7, 95% CI:
0.3-1.4), but it was associated with decreased adenocar-
cinoma risk (OR 0.2, 95% CI: 0.04-0.8). However, only
two adenocarcinomas were HIV-positive among women
infected with high-risk HPV types, and therefore this
inverse association may be a chance finding. There was
no clear association between CD4 count and SCC or
adenocarcinoma.
Discussion
The HPV types associated with both SCC and adenocar-
cinoma risk in our study have also been found to be
associated with most ICC in other regions of the world
[17,18].
SCC and HPV infection
Our study shows that SCC in Uganda is strongly asso-
ciated with any HPV infection and infection with high-
Odida et al. Infectious Agents and Cancer 2011, 6:8
http://www.infectagentscancer.com/content/6/1/8
Page 5 of 13Table 3 Risk
a of squamous cell carcinoma of the cervix for different human papillomavirus (HPV) types
HPV type HPV-positive Age adjusted
N = 203 cases & 309 controls
Age and HIV adjusted
N = 193 cases & 303 controls
Age, HIV and CD4 adjusted
N = 192 cases & 296 controls
Cases Controls OR 95% CI OR 95% CI OR 95% CI
High-risk HPV
All
b 183 54 64.5 35.4-126.6 84.7 43.5-181.6 82.3 42.2-176.8
16 101 10 29.1 15.4-60.7 28.8 15.2-60.2 27.2 14.4-56.9
18 39 8 9.6 4.6-22.3 8.9 4.2-20.6 8.3 4.0-19.2
31 2 3 0.8 0.1-4.6 0.7 0.1-3.7 0.5 0.1-2.8
33 4 5 1.3 0.3-4.7 1.2 0.3-4.4 1.4 0.3-5.6
35 10 7 2.4 0.9-6.7 2.5 0.9-6.9 2.7 1.0-8.1
39 3 1 3.7 0.6-38.9 4.2 0.7-44.4 4.2 0.7-44.2
45 18 0 58.7 >7.9
j 56.5 >7.6
j 57.2 >7.7
j
51 2 8 0.8 0.2-2.7 0.5 0.1-2.1 0.5 0.1-2.1
52 6 13 0.7 0.2-1.7 0.6 0.2-1.5 0.5 0.2-1.3
56 2 4 0.9 0.2-4.6 1.0 0.2-4.7 1.1 0.2-5.5
58 2 3 0.9 0.2-5.1 1.0 0.2-5.8 1.1 0.2-5.8
59 1 2 0.7 0.1-6.5 0.8 0.1-7.4 0.8 0.1-7.4
68/73 6 7 1.5 0.5-4.6 1.3 0.4-4.0 1.3 0.4-3.9
Low-risk HPV
All
c 5 24 0.5 0.2-1.0 0.3 0.1-0.8 0.3 0.1-0.7
6 1 3 1.0 0.1-7.0 1.1 0.1-8.0 1.1 0.1-7.9
11 0 2 0.5 <6.4
k 0.4 <5.4
k 0.3 <4.3
k
34 0 1 0.6 <11.1
k 0.4 <7.5
k 0.3 <5.3
k
40 0 1 0.7 <13.0
k 0.8 <14.7
k 0.8 <14.6
k
42 1 0 4.1 >0.2
j llll
44 0 4 0.2 <2.2
k 0.3 <2.5
k 0.2 <2.5
k
53 0 4 0.1 <1.2
k 0.1 <1.2
k 0.1 <1.1
k
54 1 3 0.4 <2.5
k 0.4 <2.8
k 0.5 <2.9
k
66 0 5 0.4 <2.2
k 0.1 <1.0
k 0.1 <1.1
k
70 1 3 0.7 0.1-4.2 0.6 0.1-3.7 0.5 0.1-3.2
74 2 4 1.0 0.1-4.2 0.9 0.2-4.6 0.8 0.1-3.8
Single inf.
d 168 49 33.3 20.2-56.7 31.5 19.1-54.0 31.0 18.7-53.5
Multiple inf.
e 15 20 1.3 0.7-2.7 1.2 0.6-2.4 1.1 0.5-2.3
16-related
f 123 36 11.6 7.5-18.5 11.9 7.6-19.0 11.4 7.2-18.3
18-related
g 66 16 9.4 5.3-17.4 8.9 5.0-16.5 8.6 4.9-16.1
HPVX
h 3 26 0.2 0.1-0.5 0.2 0.1-0.5 0.2 0.1-0.6
Any HPV
i 186 95 50.8 25.8-113.9 55.7 27.2-132.4 54.9 26.7-130.4
a OR and 95% CI.
b High-risk HPV: 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 59, 68/73.
c Low-risk HPV: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, 74.
d Single infection: infection with any of the HPV types above, except HPVX.
e Multiple infections: infections with at least two different HPV types, except HPVX.
f HPV16-related: includes HPV16, 31, 33, 35, 52 and 58.
g HPV18-related: includes HPV18, 45, 59 and 68.
h HPVX: Samples which could not be typed with any of the 25 genotypes above.
i Any HPV infection: infection with any of the HPV types above.
j Indicate only lower limit value of 95% CI.
k Indicate only upper limit value of 95% CI.
l Could not be estimated due to lack of cases with known HIV status.
Abbreviations: inf: infections, OR: odds ratio, CI: confidence interval.
Odida et al. Infectious Agents and Cancer 2011, 6:8
http://www.infectagentscancer.com/content/6/1/8
Page 6 of 13risk HPV types, in particular HPV16 (and related types),
18 (and related types) and 45. We found no evidence
that adjustment for HIV infection or CD4 decline affect
the OR for HPV infections significantly.
As in our present study, several earlier studies found
that HPV16 predominated in SCC [19]. Our study
showed higher ORs for SCC associated with HPV16
(OR 29.1, 95% CI: 15.4-60.7), which is similar to a study
from Taiwan by Chen et al. [20], where HPV16 was
associated with an OR of 67. The Taiwanese study
found substantial elevated risks for SCC associated with
HPV52 (OR 3.04) and HPV58 (OR 5.22), which were
not confirmed in our study, while the SCC risk with the
other HPV types were low. A study from Mexico also
found a high risk of cervical cancer for HPV16 and 18
[1]. The results from Mexico are exceptional in that the
OR for HPV18 was higher than that of HPV16. High
risks of cervical cancer for HPV18 have also been
reported by a number of authors [21-23]. Low risks for
HPV18 have been found in some studies from India
[24,25].
Adenocarcinomas and HPV infection
For adenocarcinoma, we found an association between
any HPV infection, in particular single infections, infec-
tions with high-risk HPV types, and most importantly
HPV16 (and related types), 18 (and related types) and
45. Adjustment for HIV infection and decline in CD4
count did not alter the associations meaningfully, sug-
gesting that there is only a small confounding effect of
HIV and its associated immune deficiency on the risk of
HPV in cervical adenocarcinoma.
HPV18 has been reported as the most frequent HPV
type found in adenocarcinoma [19]. In a pooled analysis
of case-control studies, the relative risk of HPV18 in
cervical adenocarcinoma was high (OR 410.32, 95% CI:
167.44-∞) [4]. These results were much higher than
ours for HPV18 (OR 18.5, 95% CI: 6.6-54.4).
These differences in findings across different studies
may indicate that regional factors, such as differences in
the prevalence of different HPV types, may affect ICC
risk [26]. These differential risks are probably due to the
pathogenesis of the two major types of ICC [27]. Smith
Table 4 Risk of squamous cell carcinoma of the cervix according to different human papillomavirus (HPV) types and
HIV serology
HIV-negative women HIV-positive women
HPV types Cases
(N = 162)
Controls
(N = 251)
Cases
(N = 42)
Controls
(N = 52)
HPV HPV HPV HPV
+-+- O R
a 95% CI + - + - OR
a 95% CI
High-risk
b 142 10 35 216 76.4 38.8-165.6 41 1 19 33 132.3 >17.0
j
16 78 74 7 244 32.8 15.6-78.9 23 18 3 49 16.5 5.3-67.6
18 27 125 2 249 22.3 7.1-111.8 12 29 6 46 2.9 1.0-9.1
31 0 152 2 249 0.1 <1.5
i 2 39 1 51 2.3 0.3-26.4
33 4 148 2 249 2.5 0.5-14.8 0 41 3 49 0.2 <2.7
i
35 10 142 4 247 4.5 1.5-16.0 0 41 3 49 0.2 <2.0
i
45 13 139 0 251 41.8 >5.4
j 5 36 0 52 17.1 1.8-2287
Low-risk
c 3 149 18 233 0.3 0.1-0.9 2 39 6 46 0.5 0.1-2.0
Single inf.
d 132 20 38 213 34.0 19.4-62.5 36 5 11 41 21.4 7.5-71.0
Multiple inf.
e 10 142 9 242 2.0 0.8-5.1 5 36 11 41 0.6 0.2-1.9
16-related
f 98 54 22 229 17.0 10.0-30.1 25 16 14 38 3.8 1.6-9.4
18-related
g 49 103 9 242 11.9 5.9-26.4 17 24 7 45 4.5 1.7-13.1
Any HPV
h 145 7 66 185 51.3 24.8-122.6 41 0 29 23 60.0 >7.7
j
a All ORs are age-adjusted.
b High-risk HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73.
c Low-risk HPV: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, 74.
d Single infection: infection with any of the HPV types above.
e Multiple infections: infections with at least two different HPV types.
f HPV16-related: includes HPV16, 31, 33, 35, 52 and 58.
g HPV18-related: includes HPV18, 45, 59 and 68.
h Any HPV infection: infection with any of the HPV types above.
i Indicate only upper limit value of 95% CI.
j Indicate only lower limit value of 95% CI.
Abbreviations: inf: infections, OR: odds ratio, CI: confidence interval.
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Page 7 of 13et al. [28] and Madeleine et al. [29] noted an elevated
risk of SCC associated with Trichomonas vaginalis,b u t
no associated increased risk for adenocarcinoma.
Another factor which could in theory explain the differ-
ences in SCC and adenocarcinoma risk is smoking [30];
however smoking is not common in Uganda, with a pre-
valence of only 3% among adult women [31] and 5.3%
among adolescent girls [32]. The relatively low relative
risk of ICC due to other high-risk HPV types (besides
HPV16, 18 and 45) is supported by the low prevalence
Table 5 Risk of adenocarcinoma of the cervix for different human papillomavirus (HPV) types
a
HPV type Number HPV-positive Age adjusted Age and HIV adjusted Age, HIV and CD4 adjusted
Cases Controls OR 95% CI OR 95% CI OR 95% CI
High-risk HPV
All
b 26 54 27.2 10.4-88.9 40.5 14.1-157.4 40.0 13.9-155.6
16 10 10 11.6 4.3-31.8 14.5 5.2-42.6 13.8 4.9-40.2
18 10 8 18.5 6.6-54.4 26.3 8.3-96.5 24.0 7.7-86.9
31 1 3 2.2 0.2-16.1 2.6 0.2-19.6 2.6 0.2-19.2
33 0 5 1.2 <12.2
j 1.4 <14.6
j 1.3 <14.1
j
35 0 7 0.8 <7.1
j 0.9 <8.3
j 0.8 <7.9
j
39 0 1 5.5 <108.6
j 4.7 <92.5
j 4.7 <92.5
j
45 4 0 297.4 >26.4
k 248.3 >22.1
k 247.8 >22.0
k
51 2 8 3.9 0.7-16.9 4.1 0.7-17.6 4.1 0.7-17.7
52 0 13 0.3 <2.4
j 0.4 <3.4
j 0.3 <2.9
j
56 0 4 0.8 <11.0 1.0 <12.1
j 1.0 <12.8
j
58 0 3 1.3 <15.5
j 1.3 <14.9
j 1.3 <14.9
j
59 0 2 0.9 <18.6
j 1.1 <19.27
j 1.1 <19.8
j
68/73 2 7 3.0 0.5-13.7 3.6 0.6-16.2 3.4 0.6-16.0
Low-risk HPV
All
c 1 24 0.6 0.1-2.4 0.6 0.1-2.7 0.6 0.1-2.6
6 1 3 12.8 1.1-96.7 10.0 0.9-76.0 10.0 0.9-75.9
11 0 2 3.7 <55.1
j 4.6 <64.5
j 3.8 <56.5
j
34 0 1 4.3 <82.4
j 6.4 <161
j 4.6 <126.4
j
40 0 1 5.3 <102.7
j 4.5 <88.3
j 4.5 <88.3
j
44 1 4 5.4 0.5-35.2 4.8 0.4-30.3 4.8 0.4-30.3
53 0 4 0.7 <7.6
j 0.8 <8.7
j 0.8 <8.3
j
54 0 3 0.6 <7.4
j 0.7 <8.0
j 0.7 <8.0
j
66 0 5 0.9 <9.0
j 1.2 <12.7
j 1.0 <11.2
j
70 0 3 1.3 <15.3
j 1.6 <17.7
j 1.4 <16.0
j
74 0 4 0.8 <11.1
j 0.9 <11.9
j 0.9 <11.5
j
Single inf.
d 22 49 13.7 6.0-34.0 15.5 6.6-40.5 15.3 6.5-40.0
Multiple inf.
e 4 20 2.5 0.7-7.5 3.3 0.9-10.5 3.1 0.8-9.8
16-related
f 11 36 3.6 1.5-8.2 4.9 2.0-11.6 4.7 1.9-11.2
18-related
g 16 16 22.8 9.3-58.9 26.2 10.3-71.8 24.5 9.7-67.0
HPVX
h 0 26 0.2 <1.2
b 0.2 <1.3
b 0.2 <1.5
b
Any HPV
i 26 95 12.9 5.0-41.8 18.7 6.6-71.6 18.6 6.6-71.2
a Analysis conducted with 32 cases and 309 controls.
b High-risk HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73.
c Low-risk HPV: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, 74.
d Single infection: infection with any of the HPV types above, except HPVX.
e Multiple infections: infections with at least two different HPV types, except HPVX.
f HPV16-related: includes HPV16, 31, 33, 35, 52 and 58.
g HPV18-related: includes HPV18, 45, 59 and 68.
h HPVX: Samples which could not be typed with any of the 25 genotypes above.
i Any HPV infection: infection with any of the HPV types above.
j Indicate only upper limit value of 95% CI.
k Indicate only lower limit value of 95% CI.
Abbreviations: inf: infections, OR: odds ratio, CI: confidence interval.
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Page 8 of 13of these HPV types in ICC in several other studies
[3,33], including a recent study by de Cremoux et al.
[34] which found that up to one-third of ICC were not
associated with HPV16 or 18. Some of these high-risk
HPV types, namely HPV31, 33, 52 and 58, have been
found to be more prevalent in high-grade intraepithelial
cervical lesions than in SCC [17].
As possible caveats, our study was limited by the
number of probes for HPV, which only allowed us to
detect 25 HPV genotypes. These are, however, the most
important HPV types described in the literature as
being associated with cervical lesions including ICC.
Moreover, the SPF10-LiPA25 HPV test used in our study
(version 1, produced at Labo Biomedical Products, Rijs-
wijk, the Netherlands) is highly sensitive for the HPV
types tested. We tested HPV-negative ICC samples for
beta-globin, and excluded from all analyses those
women whose samples were beta-globin-negative. Thus,
the samples included in our analysis were of sufficient
quality to allow HPV detection. However, since cases
were in general presenting at advanced stages (3 and 4),
it is possible that HPV could no longer be detected in
the cervical cells of some patients, which may explain
why a small proportion of our cases were HPV-negative.
This could have somewhat biased the OR for the asso-
ciations between HPV and ICC towards unity.
HIV and CD4 count
Of particular interest was the lack of clear association
between HIV infection and decline in CD4 count on the
risk for SCC in our entire study population, and in the
subset of women infected with high-risk HPV types.
Although there was a non-significant increase in SCC
risk associated with HIV infection, it is not probable
that this effect was due to immune depression on dis-
ease progression, since the OR was not decreased when
adjusting for CD4 count.
For adenocarcinomas, there was no evidence of asso-
ciation with HIV infection in the entire study popula-
tion, regardless of adjustment for different HPV types or
groups of types and CD4 count. However, there was an
inverse association between HIV infection and adeno-
carcinoma risk when restricting the analysis to women
who were infected with high-risk HPV types. There was
no association between CD4 count and adenocarcinoma
risk when analysing all women in our study, or when
Table 6 Risk of adenocarcinoma of the cervix according to different human papillomavirus (HPV) types and HIV
serology
HIV-negative women HIV-positive women
HPV types Cases
(N = 28)
Controls
(N = 251)
Cases
(N = 4)
Controls
(N = 52)
HPV HPV HPV HPV
+-+ -O R
a 95% CI + - + - OR
a 95% CI
High-risk
b 24 3 53 216 39.5 13.6-153.8 2 0 19 33 8.8 0.7-1235
16 8 19 7 244 11.0 3.6-34.2 2 0 3 49 108.2 >4.0
i
18 10 17 2 249 57.9 14.8-327.8 0 2 6 46 1.3 <20.8
j
31 1 26 2 249 2.8 0.2-24.2 0 2 1 51 6.0 <149.8
j
33 0 27 2 249 1.8 <23.7
j 0 2 3 49 3.5 <71.4
j
45 4 23 0 251 251.3 >22.2
i 0205 2
kk
Low-risk
c 1 26 18 233 0.7 0.1-3.2 2 0 6 46 1.4 <19.8
j
Single inf.
d 7 20 38 213 14.5 6.0-38.2 2 0 11 41 15.0 1.2-2086
Multiple inf.
e 4 23 9 242 5.0 1.3-16.9 2 0 11 41 0.9 <11.0
j
16-related
f 9 18 22 229 4.3 1.6-10.5 2 0 14 38 12.8 1.0-1794
18-related
g 16 11 7 244 42.2 15.0-133.8 0 2 7 45 1.3 <17.8
j
Any HPV
h 24 3 66 185 18.3 6.4-70.0 2 0 29 23 4.0 0.3-565.6
a All ORs are age-adjusted.
b High-risk HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73.
c Low-risk HPV: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, 74.
d Single infection: infection with any of the HPV types above.
e Multiple infections: infections with at least two different HPV types.
f HPV16-related: includes HPV16, 31, 33, 35, 52 and 58.
g HPV18-related: includes HPV18, 45, 59 and 68.
h Any HPV infection: infection with any of the HPV types above.
i Indicate only lower limit value of 95% CI.
j Indicate only upper limit value of 95% CI.
k Could not be estimated due to lack of cases with known HIV status.
Abbreviations: inf: infections, OR: odds ratio, CI: confidence interval.
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Page 9 of 13restricting the analyses to the subset of women infected
with high-risk HPV types. These finding must be inter-
preted with caution, as the number of HIV-positive
women in our study, in particular among adenocarci-
noma cases, was small, and therefore we cannot rule out
the possibility of a chance finding.
The overall HPV prevalence among HIV-positive con-
trol women was higher than among HIV-negative con-
trol women. This may be explained by common sexual
transmission routes, or it may be a reflection of the
HIV-associated decrease in immune response, which
increases the probability of being infected with HPV,
and of clearing the infection less effectively than women
who are not infected with HIV. As a consequence, the
association between HPV infection and ICC among
HIV-positive women was in general weaker than among
HIV-negative women.
Several previous studies have shown varying risk of
ICC in association with HIV infection [12,35-41]. Earlier
studies suggested that a possible increase in cervical
cancer risk among HIV-positive women could be attrib-
uted to the increased prevalence of HPV infection, or
persistence of HPV infection [42,43]. In addition, CIN is
less likely to regress, and therefore the probability of
CIN progressing to ICC is increased in HIV-infected
women [43]. This has been attributed to reduced HLA
Table 7 Odds ratios (OR) and 95% confidence intervals (CI) for squamous cell carcinoma and adenocarcinoma of the
cervix according to HIV infection and adjustment factors: age, CD4 count (decrease of 100 cells), and human
papillomavirus (HPV) types
Squamous cell carcinoma
N = 246 cases, 308 controls
a
Adenocarcinoma
N = 39 cases, 308 controls
b
Adjustment factor OR for HIV-positive vs. HIV-negative 95% CI OR for HIV-positive vs. HIV-negative 95% CI
Age 1.5 0.9-2.3 1.1 0.4-2.7
Age + CD4 1.6 1.0-2.6 0.8 0.1-2.6
Age + CD4 + HPV16 1.6 0.9-2.9 0.5 0.1-1.8
Age + CD4 + HPV16-related
c 1.4 0.7-2.4 0.5 0.1-1.6
Age + CD4 + HPV18 1.4 0.8-2.4 0.3 <1.2
j
Age + CD4 + HPV18-related
d 1.4 0.8-2.4 0.4 0.1-1.5
Age + CD4 + High-risk HPV
e 0.6 0.3-1.1 0.3 <0.9
j
Age + CD4 + Low-risk HPV
f 1.9 1.1-3.2 0.8 0.2-2.6
Age + CD4 + Single HPV inf.
g 1.2 0.6-2.4 0.5 0.1-1.7
Age + CD4 + Multiple HPV inf.
h 1.8 1.1-3.0 0.6 0.1-2.0
Age + CD4 + Any HPV inf.
i 0.8 0.4-1.4 0.4 0.1-1.2
a HIV-positive: 48 cases, 54 controls.
b HIV-positive: 5 cases, 54 controls.
c HPV16-related: includes HPV16, 31, 33, 35, 52 and 58.
d HPV18-related: includes HPV18, 45, 59 and 68.
e High-risk HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73.
f Low-risk HPV: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, 74.
g Single infection: infection with any of the HPV types above.
h Multiple infections: infections with at least two different HPV types.
i Any HPV infection: infection with any of the HPV types above.
j Indicate only lower limit value of 95% CI.
Abbreviations: inf: infections,.
Table 8 Age adjusted odds ratio (OR) and 95%
confidence interval (CI) for invasive cervical carcinoma
according to HIV serology and CD4 count among women
who are infected with high-risk human papillomavirus
(HPV) types
a
Controls Squamous cell
carcinoma
Adenocarcinoma
Number Number OR 95%
CI
Number OR 95%
CI
HIV
Any
(+or-)
54 183 26
Negative 35 142 1.0
(ref)
24 1.0
(ref)
Positive 19 41 0.7 0.3-
1.4
2 0.2 0.04-
0.8
CD4 count
Any 37 135 21
>300 33 113 1.0
(ref)
19 1.0
(ref)
≤300 4 22 1.8 0.6-
6.2
2 1.8 0.3-
10.1
>500 26 90 1.0
(ref)
15 1.0
(ref)
≤500 11 45 1.4 0.6-
3.3
6 0.9 0.3-
3.1
aHigh-risk HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73.
NOTE: CD4 count classified according to two different cut-points: 300 and 500 cells.
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Page 10 of 13class II molecules and the presence of immature Langer-
hans cells within the cervical tissue in HIV-infected
women [44]. Other studies have suggested that HPV
types other than 16 or 18 are more prevalent in HIV-
positive women [19,45], and that the median duration of
infections with different individual HPV types lasts
longer in HIV-positive women as compared to HIV-
negative women, with the exception of HPV16, which
seem to be similar [46,47]. This indicates that the prob-
ability of progression of cervical pre-invasive lesions to
invasive lesions may be increased among HIV-positive
women.
In our case-control study design, cases were recruited
when ICC was already present, and exposures were
measured at the time subjects were recruited into the
study. Thus, we do not know if HIV infection, or if
decrease in CD4 count, occurred before or after the
onset of HPV infection or cervical lesions. It is possible
that some HIV infections occurred before the onset of
HPV infections and before the development cervical
pre-invasive or invasive lesions. HIV infection could also
have occurred while women were infected with HPV,
thus eventually decreasing their capacity to clear the
infection. It is also plausible that HIV infections may
have occurred too late in life to have any effect on the
occurrence or persistence of HPV infection, as suggested
by a study from Nairobi, Kenya [48].
The lack of association between HIV infection, CD4
count and SCC risk in our study could also be explained
by the fact that progression of CIN to ICC is multifac-
torial, and not dependent on immune status only [49],
by the existence of slow progressors [50,51] or elite con-
trollers [52,53] in some women, or by the possibility
that HIV and CD4 count have no role in the progres-
sion of cervical cancer.
Our study had a number of advantages compared to
previous studies. We enrolled all consecutive patients
suspected to have ICC, aiming to reduce bias that could
occur if any criteria associated with the exposure were
used to select ICC cases, for example stage, duration of
symptoms, tribe, etc. While other studies have used
women with other disease conditions as controls
[11,12], we were able to use women who were not hos-
pitalised, had no cervical disease (CIN cases were
excluded), and were living in the same geographical
areas as ICC cases. Further, they were representative of
the population base from where the cases arose. Since
the evaluation of family history of cervical cancer was
not part of our study hypothesis, the inclusion of blood
relatives of the ICC cases as controls did not constitute
a problem.
Another strength was that we carried out the study in
an area where both HIV prevalence [14] and cervical
cancer incidence are high [13]. This allowed us to adjust
for HIV status and decline in CD4 count in our HPV
analysis, as well as to perform stratified analyses by HIV
status to assess the impact of HIV infection per se and
the HPV risk associated with HIV status on ICC.
Our study had a relatively small number of HIV-posi-
tive SCC and, in particular, adenocarcinoma. In addi-
tion, assessment of immunity was based only on CD4
count, which may reflect HIV infection on the systemic
immune system. Although CD4 count has been used
before [54], it is difficult to know when immunodefi-
ciency sets in. The statistical power for detecting cancer
risk in subgroups of HIV-infected women was limited,
in particular for adenocarcinoma.
Conclusions
In conclusion, the OR for SCC and adenocarcinoma of
the cervix in Uganda were increased in women infected
with HPV, in particular single HPV infections, infections
with HPV16- and 18-related types and infections with
high-risk HPV types, specifically with HPV16, 18 and
45. HIV infection and CD4 count were not clearly asso-
ciated with SCC or adenocarcinoma in our entire study
population. Among women infected with high-risk HPV
types, there was no association between SCC, HIV and
CD4 count, while there was an inverse association
between HIV infection - but not CD4 count - and
adenocarcinoma.
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